Literature DB >> 11959793

Mouse beta 3a- and beta 3b-adrenoceptors expressed in Chinese hamster ovary cells display identical pharmacology but utilize distinct signalling pathways.

Dana S Hutchinson1, Tore Bengtsson, Bronwyn A Evans, Roger J Summers.   

Abstract

1. This study characterizes the mouse beta(3a)-adrenoceptor (AR) and the splice variant of the beta(3)-AR (beta(3b)-AR) expressed in Chinese hamster ovary cells (CHO-K1). 2. Stable clones with high (approximately 1200), medium (approximately 500) or low receptor expression (approximately 100 fmol mg protein(-1)) were determined by saturation binding with [(125)I]-(-)-cyanopindolol. Competition binding studies showed no significant differences in affinity of beta-AR ligands for either receptor. 3. Several functional responses of each receptor were measured, namely extracellular acidification rate (EAR; cytosensor microphysiometer), cyclic AMP accumulation, and Erk1/2 phosphorylation. The beta(3)-AR agonists BRL37344, CL316243, GR265162X, L755507, SB251023, the non-conventional partial beta-AR agonist CGP12177 and the beta-AR agonist (-)-isoprenaline caused concentration-dependent increases in EAR in cells expressing either splice variant. CL316243 caused concentration-dependent increases in cyclic AMP accumulation and Erk1/2 phosphorylation in cells expressing either receptor. 4. PTX treatment increased maximum EAR and cyclic AMP responses to CL316243 in cells expressing the beta(3b)-AR but not in cells expressing the beta(3a)-AR at all levels of receptor expression. 5. CL316243 increased Erk1/2 phosphorylation with pEC(50) values and maximum responses that were not significantly different in cells expressing either splice variant. Erk1/2 phosphorylation was insensitive to PTX or H89 (PKA inhibitor) but was inhibited by LY294002 (PI3K gamma inhibitor), PP2 (c-Src inhibitor), genistein (tyrosine kinase inhibitor) and PD98059 (MEK inhibitor). 6. The adenylate cyclase activators forskolin or cholera toxin failed to increase Erk1/2 levels although both treatments markedly increased cyclic AMP accumulation in both beta(3a)- or beta(3b)-AR transfected cells. 7. These results suggest that in CHO-K1 cells, the beta(3b)-AR, can couple to both G(s) and G(i) to stimulate and inhibit cyclic AMP production respectively, while the beta(3a)-AR, couples solely to G(s) to increase cyclic AMP levels. However, the increase in Erk1/2 phosphorylation following receptor activation is not dependent upon coupling of the receptors to G(i) or the generation of cyclic AMP.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11959793      PMCID: PMC1573318          DOI: 10.1038/sj.bjp.0704654

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  39 in total

1.  Parathyroid hormone activates mitogen-activated protein kinase via a cAMP-mediated pathway independent of Ras.

Authors:  M H Verheijen; L H Defize
Journal:  J Biol Chem       Date:  1997-02-07       Impact factor: 5.157

Review 2.  Agonist-receptor efficacy. I: Mechanisms of efficacy and receptor promiscuity.

Authors:  T Kenakin
Journal:  Trends Pharmacol Sci       Date:  1995-06       Impact factor: 14.819

Review 3.  Agonist-receptor efficacy. II. Agonist trafficking of receptor signals.

Authors:  T Kenakin
Journal:  Trends Pharmacol Sci       Date:  1995-07       Impact factor: 14.819

4.  Differential interaction of beta 1- and beta 3-adrenergic receptors with Gi in rat adipocytes.

Authors:  A Chaudhry; R G MacKenzie; L M Georgic; J G Granneman
Journal:  Cell Signal       Date:  1994-05       Impact factor: 4.315

5.  Agonist potency at the cloned human beta-3 adrenoceptor depends on receptor expression level and nature of assay.

Authors:  S Wilson; J K Chambers; J E Park; A Ladurner; D W Cronk; C G Chapman; H Kallender; M J Browne; G J Murphy; P W Young
Journal:  J Pharmacol Exp Ther       Date:  1996-10       Impact factor: 4.030

6.  Triiodothyronine and amiodarone effects on beta 3-adrenoceptor density and lipolytic response to the beta 3-adrenergic agonist BRL 37344 in rat white adipocytes.

Authors:  R Germack; H Adli; R Vassy; G Y Perret
Journal:  Fundam Clin Pharmacol       Date:  1996       Impact factor: 2.748

7.  Two isoforms of the prostaglandin E receptor EP3 subtype different in agonist-independent constitutive activity.

Authors:  H Hasegawa; M Negishi; A Ichikawa
Journal:  J Biol Chem       Date:  1996-01-26       Impact factor: 5.157

8.  Regulation of mouse beta 3-adrenergic receptor gene expression and mRNA splice variants in adipocytes.

Authors:  J G Granneman; K N Lahners
Journal:  Am J Physiol       Date:  1995-04

9.  Determination of structural domains for G protein coupling and ligand binding in beta 3-adrenergic receptor.

Authors:  X M Guan; A Amend; C D Strader
Journal:  Mol Pharmacol       Date:  1995-09       Impact factor: 4.436

10.  The 5-HT4 receptor: molecular cloning and pharmacological characterization of two splice variants.

Authors:  C Gerald; N Adham; H T Kao; M A Olsen; T M Laz; L E Schechter; J A Bard; P J Vaysse; P R Hartig; T A Branchek
Journal:  EMBO J       Date:  1995-06-15       Impact factor: 11.598

View more
  18 in total

1.  Interaction with caveolin-1 modulates G protein coupling of mouse β3-adrenoceptor.

Authors:  Masaaki Sato; Dana S Hutchinson; Michelle L Halls; Sebastian G B Furness; Tore Bengtsson; Bronwyn A Evans; Roger J Summers
Journal:  J Biol Chem       Date:  2012-04-25       Impact factor: 5.157

Review 2.  GRK2 as negative modulator of NO bioavailability: Implications for cardiovascular disease.

Authors:  Alessandro Cannavo; Walter J Koch
Journal:  Cell Signal       Date:  2017-01-07       Impact factor: 4.315

3.  β(3) Receptors: Role in Cardiometabolic Disorders.

Authors:  Shraddha V Bhadada; Bhoomika M Patel; Anita A Mehta; Ramesh K Goyal
Journal:  Ther Adv Endocrinol Metab       Date:  2011-04       Impact factor: 3.565

4.  The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors.

Authors:  Stephen P H Alexander; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Michael Spedding; John A Peters; Anthony J Harmar
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

Review 5.  Tools to study beta3-adrenoceptors.

Authors:  Wim Vrydag; Martin C Michel
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-01-09       Impact factor: 3.000

Review 6.  Mirabegron: potential off target effects and uses beyond the bladder.

Authors:  Nodi Dehvari; Edilson Dantas da Silva Junior; Tore Bengtsson; Dana Sabine Hutchinson
Journal:  Br J Pharmacol       Date:  2018-01-18       Impact factor: 8.739

Review 7.  Beta 3-adrenoreceptor regulation of nitric oxide in the cardiovascular system.

Authors:  An L Moens; Ronghua Yang; Vabren L Watts; Lili A Barouch
Journal:  J Mol Cell Cardiol       Date:  2010-02-23       Impact factor: 5.000

8.  Role of β-adrenoceptors in glucose uptake in astrocytes using β-adrenoceptor knockout mice.

Authors:  Stephanie L Catus; Marie E Gibbs; Masaaki Sato; Roger J Summers; Dana S Hutchinson
Journal:  Br J Pharmacol       Date:  2011-04       Impact factor: 8.739

9.  Agonist effects of zinterol at the mouse and human beta(3)-adrenoceptor.

Authors:  Dana S Hutchinson; Ekaterina Chernogubova; Masaaki Sato; Roger J Summers; Tore Bengtsson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-04-07       Impact factor: 3.000

10.  Signaling pathways mediating beta3-adrenergic receptor-induced production of interleukin-6 in adipocytes.

Authors:  Inna E Tchivileva; Kai Soo Tan; Maria Gambarian; Andrea G Nackley; Alexander V Medvedev; Sergei Romanov; Patrick M Flood; William Maixner; Sergei S Makarov; Luda Diatchenko
Journal:  Mol Immunol       Date:  2009-05-23       Impact factor: 4.407

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.